Bimekizumab: A novel FDA approved dual IL-17 A/F inhibitor for moderate to severe psoriasis.

Authors

Febin Ashraf, Simin Muhammed Kutty

Published in

Indian journal of dermatology, venereology and leprology. Pages 1-5. Dec 11, 2024. Epub Dec 11, 2024.

PMID:
39912180
Bibliographic data and abstract were imported from PubMed on 06 Feb 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.